Core Insights - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [4] Conference Participation - The company will present at the American Society of Nephrology Kidney Week 2025 from November 5 to 9, 2025, in Houston, TX, USA, with a presentation titled "Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial" scheduled for November 6 [2] - Additionally, the company will participate in 1x1 meetings at the Jefferies Global Healthcare Conference from November 18 to 20, 2025, in London, UK [3] - The company will also attend the Deutsches Eigenkapitalforum from November 24 to 26, 2025, in Frankfurt, Germany [3] Product Development - Vivoryon's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [4]